Recent Advancements in the 3D Printing of Pharmaceutics

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmaceutical Technology, Manufacturing and Devices".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 1750

Special Issue Editor


E-Mail Website
Guest Editor
Principal Scientist, College of Pharmacy, University of Mississippi, Oxford, MS 38677, USA
Interests: bioprinting; 3D printing; nanoparticles; mRNA therapeutics; long term drug release implant; drug delivery

Special Issue Information

Dear Colleagues,

I am happy to invite you all to submit your research to the esteemed journal Pharmaceutics, where the new Special Issue titled ‘Recent Advancements in the 3D Printing of Pharmaceutics’ will cover new materials, 3D printing methodologies, drug formulations, AI/ML applications, and more. The major focus of this Special Issue is to highlight cutting-edge research in developing new ways of formulating and fabricating drug dosage forms for continuous and portable manufacturing needs in established and remote places or regions. Your research will be highlighted through this Special Issue to international audiences worldwide. Take advantage of the open-source publishing at MDPI to allow every researcher around the world to access your research.

Dr. L. R.Jaidev Chakka
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • 3D printing
  • pharmaceutics
  • AI/ML
  • drug formulations
  • 3D printing methods.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 6017 KiB  
Article
Comparison of Two Synthesis Methods for 3D PLA-Ibuprofen Nanofibrillar Scaffolds
by Esteban Mena-Porras, Annaby Contreras-Aleman, María Francinie Guevara-Hidalgo, Esteban Avendaño Soto, Diego Batista Menezes, Marco Antonio Alvarez-Perez and Daniel Chavarría-Bolaños
Pharmaceutics 2025, 17(1), 106; https://doi.org/10.3390/pharmaceutics17010106 - 14 Jan 2025
Viewed by 1172
Abstract
Objectives: This study aimed to synthesize polylactic acid (PLA) nanofibrillar scaffolds loaded with ibuprofen (IBU) using electrospinning (ES) and air-jet spinning (AJS). The scaffolds were evaluated for their physicochemical properties, drug release profiles, and biocompatibility to assess their potential for local analgesic applications. [...] Read more.
Objectives: This study aimed to synthesize polylactic acid (PLA) nanofibrillar scaffolds loaded with ibuprofen (IBU) using electrospinning (ES) and air-jet spinning (AJS). The scaffolds were evaluated for their physicochemical properties, drug release profiles, and biocompatibility to assess their potential for local analgesic applications. Methods: Solutions of 10% (w/v) PLA combined with IBU at concentrations of 10%, 20%, and 30% were processed into nanofibrillar membranes using ES and AJS. The scaffolds were characterized using scanning electron microscopy (SEM), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and Fourier-transformed infrared (FT-IR) spectroscopy. The drug release profile was assessed by ultraviolet-visible spectrophotometry (UV-Vis), and cell adhesion and viability were evaluated using fibroblast culture assays. Statistical analyses included qualitative analyses, t-tests, and Likelihood ratio tests. Results: SEM revealed randomly arranged nanofibers forming reticulated meshes, with more uniform dimensions observed in the AJS group. TGA and DSC analyses confirmed the thermodynamic stability of the scaffolds and enthalpy changes consistent with IBU incorporation, which FT-IR and UV-Vis validated. Drug release was sustained over 384 h, showing no significant differences between ES and AJS scaffolds (p > 0.05). Cytotoxicity and cell viability assays confirmed scaffold biocompatibility, with cellular responses proportional to drug concentration but within safe limits. Conclusions: PLA-IBU nanofibrillar scaffolds were successfully synthesized using ES and AJS. Both methods yielded biocompatible systems with stable properties and controlled drug release. Further, in vivo studies are necessary to confirm their clinical potential. Full article
(This article belongs to the Special Issue Recent Advancements in the 3D Printing of Pharmaceutics)
Show Figures

Figure 1

Back to TopTop